Generics specialist Mylan (Nasdaq: MYL) on Friday reported better than estimated third-quarter 2015 earnings.
The company reported earnings per share of $1.43, compared with $1.16 a year ago. Revenue for the quarter stood at $2.71 billion up 36% on a constant currency basis versus the prior year period. Adjusted gross profit of $1.58 billion was up 39% year on year.
The company said it sees full-year adjusted earnings at the high end of 2015 guidance of $4.15 to $4.35 on the back of business continuing to hit on all cylinders, as well as the recent developments with respect to EpiPen Auto-Injector.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze